• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Staging of renal cell carcinoma: Current concepts.肾细胞癌的分期:当前概念
Indian J Urol. 2009 Oct-Dec;25(4):446-54. doi: 10.4103/0970-1591.57906.
2
Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.2005年肾细胞癌:分期、预后评估及靶向分子治疗的新前沿
J Urol. 2005 Jun;173(6):1853-62. doi: 10.1097/01.ju.0000165693.68449.c3.
3
Prognostic factors in renal cell carcinoma.肾细胞癌的预后因素
Semin Oncol. 2006 Oct;33(5):563-75. doi: 10.1053/j.seminoncol.2006.06.006.
4
Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma.肾细胞癌手术治疗的演变原则及预后因素
J Clin Oncol. 2006 Dec 10;24(35):5565-75. doi: 10.1200/JCO.2006.08.1794.
5
Prognostic factors and selection for clinical studies of patients with kidney cancer.肾癌患者临床研究的预后因素与选择
Crit Rev Oncol Hematol. 2008 Mar;65(3):235-62. doi: 10.1016/j.critrevonc.2007.08.003. Epub 2007 Oct 10.
6
Role of molecular markers in the diagnosis and therapy of renal cell carcinoma.分子标志物在肾细胞癌诊断和治疗中的作用。
Urology. 2005 Nov;66(5 Suppl):1-9. doi: 10.1016/j.urology.2005.06.112.
7
Prognostic factors in renal cell carcinoma.肾细胞癌的预后因素。
World J Urol. 2010 Jun;28(3):319-27. doi: 10.1007/s00345-010-0540-8. Epub 2010 Apr 3.
8
Identification and validation of novel prognostic markers in Renal Cell Carcinoma.肾细胞癌中新型预后标志物的鉴定与验证
Dan Med J. 2017 Oct;64(10).
9
The staging of renal cell carcinoma.肾细胞癌的分期
Curr Opin Urol. 2008 Sep;18(5):455-61. doi: 10.1097/MOU.0b013e32830a4f36.
10
TNM staging system for renal-cell carcinoma: current status and future perspectives.肾细胞癌的TNM分期系统:现状与未来展望。
Lancet Oncol. 2007 Jun;8(6):554-8. doi: 10.1016/S1470-2045(07)70173-0.

引用本文的文献

1
iRECIST-based versus non-standardized free text reporting of CT scans for monitoring metastatic renal cell carcinoma: a retrospective comparison.基于 iRECIST 标准与非标准化自由文本报告对转移性肾细胞癌 CT 扫描监测的回顾性比较。
J Cancer Res Clin Oncol. 2022 Aug;148(8):2003-2012. doi: 10.1007/s00432-022-03997-0. Epub 2022 Apr 14.
2
MRI-Based Grading of Clear Cell Renal Cell Carcinoma Using a Machine Learning Classifier.使用机器学习分类器基于MRI对透明细胞肾细胞癌进行分级
Front Oncol. 2021 Oct 1;11:708655. doi: 10.3389/fonc.2021.708655. eCollection 2021.
3
Regulation of Long Non-Coding RNAs by Plant Secondary Metabolites: A Novel Anticancer Therapeutic Approach.植物次生代谢产物对长链非编码RNA的调控:一种新型抗癌治疗方法。
Cancers (Basel). 2021 Mar 13;13(6):1274. doi: 10.3390/cancers13061274.
4
Nucleobindin-2 enhances the epithelial-mesenchymal transition in renal cell carcinoma.核结合蛋白-2促进肾细胞癌的上皮-间质转化。
Oncol Lett. 2020 Jun;19(6):3653-3664. doi: 10.3892/ol.2020.11526. Epub 2020 Apr 10.
5
CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma.CLEC3B 在肾透明细胞癌中表达下调并抑制其增殖。
Oncol Rep. 2018 Oct;40(4):2023-2035. doi: 10.3892/or.2018.6590. Epub 2018 Jul 23.
6
Tumor thrombus: incidence, imaging, prognosis and treatment.肿瘤血栓:发病率、影像学、预后及治疗
Cardiovasc Diagn Ther. 2017 Dec;7(Suppl 3):S165-S177. doi: 10.21037/cdt.2017.09.16.
7
Pathological upstaging of clinical T1 renal cell carcinoma: an analysis of 115,835 patients from National Cancer Data Base, 2004-2013.临床T1期肾细胞癌的病理分期上调:对2004 - 2013年国家癌症数据库中115,835例患者的分析
Int Urol Nephrol. 2018 Feb;50(2):237-245. doi: 10.1007/s11255-017-1768-7. Epub 2017 Dec 15.
8
Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma model.一种Kunitz型抑制剂在小鼠肾细胞癌模型中的良好药理学特性。
Oncotarget. 2016 Sep 20;7(38):62255-62266. doi: 10.18632/oncotarget.11555.
9
Correlation between BOLD-MRI and HIF expression level in renal carcinoma.肾癌中血氧水平依赖性功能磁共振成像(BOLD-MRI)与低氧诱导因子(HIF)表达水平的相关性
Int J Clin Exp Pathol. 2015 Oct 1;8(10):13759-63. eCollection 2015.
10
Standard b-value versus low b-value diffusion-weighted MRI in renal cell carcinoma: a systematic review and meta-analysis.标准b值与低b值扩散加权磁共振成像在肾细胞癌中的应用:一项系统评价和荟萃分析
BMC Cancer. 2014 Nov 18;14:843. doi: 10.1186/1471-2407-14-843.

本文引用的文献

1
Patients with distant metastases from renal cell carcinoma can be accurately identified: external validation of a new nomogram.肾细胞癌远处转移患者可被准确识别:一种新的列线图的外部验证
BJU Int. 2008 Jan;101(1):39-43. doi: 10.1111/j.1464-410X.2007.07170.x. Epub 2007 Oct 1.
2
Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma.肾外肿瘤扩展的位置不影响pT3a期肾细胞癌患者的生存率。
J Urol. 2007 Nov;178(5):1878-82. doi: 10.1016/j.juro.2007.07.011. Epub 2007 Sep 17.
3
Prognostic factors for renal cell carcinoma with tumor thrombus extension.伴有肿瘤血栓延伸的肾细胞癌的预后因素
J Urol. 2007 Oct;178(4 Pt 1):1189-95; discussion 1195. doi: 10.1016/j.juro.2007.05.134. Epub 2007 Aug 14.
4
Patients with renal cell carcinoma nodal metastases can be accurately identified: external validation of a new nomogram.肾细胞癌淋巴结转移患者可被准确识别:一种新的列线图的外部验证
Int J Cancer. 2007 Dec 1;121(11):2556-61. doi: 10.1002/ijc.23010.
5
Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience.肿瘤大小对pT2期肾细胞癌的预后影响:一项国际多中心研究经验
J Urol. 2007 Jul;178(1):35-40; discussion 40. doi: 10.1016/j.juro.2007.03.046. Epub 2007 May 22.
6
Redefining pT3 renal cell carcinoma in the modern era: a proposal for a revision of the current TNM primary tumor classification system.现代重新定义pT3期肾细胞癌:关于修订当前TNM原发肿瘤分类系统的提议
Cancer. 2007 Jun 15;109(12):2439-44. doi: 10.1002/cncr.22713.
7
Multi-institutional validation of a new renal cancer-specific survival nomogram.一种新型肾癌特异性生存列线图的多机构验证
J Clin Oncol. 2007 Apr 10;25(11):1316-22. doi: 10.1200/JCO.2006.06.1218.
8
Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience.T3a期肾细胞癌肿瘤大小的预后相关性:一项多中心研究经验
Eur Urol. 2007 Jul;52(1):155-62. doi: 10.1016/j.eururo.2007.01.106. Epub 2007 Feb 7.
9
Cancer statistics, 2007.2007年癌症统计数据。
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66. doi: 10.3322/canjclin.57.1.43.
10
Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival.无远处转移疾病的伴有淋巴结转移的肾细胞癌:疾病特异性生存的预后指标
Eur Urol. 2007 Jun;51(6):1616-24. doi: 10.1016/j.eururo.2006.12.015. Epub 2006 Dec 14.

肾细胞癌的分期:当前概念

Staging of renal cell carcinoma: Current concepts.

作者信息

Lam John S, Klatte Tobias, Breda Alberto

机构信息

Roy and Patricia Disney Family Cancer Center, Providence Saint Joseph Medical Center, Burbank, CA 91505, USA.

出版信息

Indian J Urol. 2009 Oct-Dec;25(4):446-54. doi: 10.4103/0970-1591.57906.

DOI:10.4103/0970-1591.57906
PMID:19955666
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2808645/
Abstract

The most important and widely utilized system for providing prognostic information following surgical management for renal cell carcinoma (RCC) is currently the tumor, nodes, and metastasis (TNM) staging system. An accurate and clinically useful staging system is an essential tool used to provide patients with counseling regarding prognosis, select treatment modalities, and determining eligibility for clinical trials. Data published over the last few years has led to significant controversies as to whether further revisions are needed and whether improvements can be made with the introduction of new, more accurate predictive prognostic factors. Staging systems have also evolved with an increase in the understanding of RCC tumor biology. Molecular tumor biomarkers are expected to revolutionize the staging of RCC by providing more effective prognostic ability over traditional clinical variables alone. This review will examine the components of the TNM staging system, current staging modalities including comprehensive integrated staging systems, and predictive nomograms, and introduce the concept of molecular staging for RCC.

摘要

目前,用于提供肾细胞癌(RCC)手术治疗后预后信息的最重要且应用最广泛的系统是肿瘤、淋巴结和转移(TNM)分期系统。准确且临床实用的分期系统是用于为患者提供预后咨询、选择治疗方式以及确定临床试验资格的重要工具。过去几年发表的数据引发了关于是否需要进一步修订以及引入新的、更准确的预测预后因素是否能带来改善的重大争议。随着对RCC肿瘤生物学认识的增加,分期系统也在不断演变。分子肿瘤生物标志物有望通过单独提供比传统临床变量更有效的预后能力,彻底改变RCC的分期。本综述将审视TNM分期系统的组成部分、当前的分期方式,包括综合集成分期系统和预测列线图,并介绍RCC分子分期的概念。